Robert W. Baird analyst Eric Coldwell maintained a Buy rating on Quest Diagnostics (NYSE:DGX) Inc on Monday, setting a price target of $137, which is approximately 11.06% above the present share price of $123.36.
Coldwell expects Quest Diagnostics Inc to post earnings per share (EPS) of $4.28 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Quest Diagnostics, with an average price target of $143.67.
The analysts price targets range from a high of $158 to a low of $136.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $3 billion and a net profit of $795 million. The company's market cap is $16.46 billion.
According to TipRanks.com, Robert W. Baird analyst Eric Coldwell is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.4% and a 61.47% success rate.
Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.